http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20170100213-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fe76949cd566430d9d83a068bab21e1 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57438 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2016-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbe3ba18671136d13226bb40e1f57dcc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b66b6fbe51b72e8069d5dade4bb2e9b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e06ab0abc9ee7c4b1d73a9dbbe8c8631 |
| publicationDate | 2017-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20170100213-A |
| titleOfInvention | Composition and method for detecting a diagnostic marker for renal cell carcinoma |
| abstract | The present invention relates to a composition for diagnosing renal cancer and a diagnostic marker detecting method. More particularly, the present invention relates to glycyl-tRNA synthetase (GRS), histidyl-tRNA synthetase (HRS), and aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1 (AIMP1) And a method for detecting the marker from a sample obtained from a subject to provide information necessary for diagnosing kidney cancer. The present invention also provides a method for detecting a marker of kidney cancer, comprising the steps of: . The inventive kidney cancer diagnostic markers of GRS, HRS and AIMP1 have increased expression levels in the serum of patients with kidney cancer compared to normal control. Thus, the presence or absence of kidney cancer can be determined accurately and quickly by measuring the expression levels of one or more markers selected from the group consisting of GRS, HRS and AIMP1. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021531041-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111944898-A |
| priorityDate | 2016-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1552.